Lightnews — Scholar-powered news

Reposted by Mo. Elrggal

Cristina Popa @nephroseeker.medsky.social · Sep 6

Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy

Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation

However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com

Last Month in Nephrology

lastmonthinnephrology.wordpress.com

1 4 11

Reposted by Mo. Elrggal

Nephrology Journal Club @nephjc.bsky.social · Sep 6

🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky

@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts

*the original article from @asnpublications.bsky.social

www.nephjc.com/news/nephjc-...

NephJC Shorts: MCD and FSGS Outcomes — NephJC

A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD

www.nephjc.com

2 8 8

Reposted by Mo. Elrggal

Nephrology Journal Club @nephjc.bsky.social · Jul 21

On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff

Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

www.nephjc.com

22 37

Mo. Elrggal @kidneyman.bsky.social · Jul 13

Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...

1 2

Reposted by Mo. Elrggal

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jul 2

We don’t get to discuss every important study that comes out on #NephJC

Hence #NephJCShorts

www.nephjc.com/news/nephjc-...

Introducing NephJC Shorts — NephJC

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

www.nephjc.com

1 9 15

Reposted by Mo. Elrggal

ISNkidneycare @theisn.org · Jul 3

Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6...

Clinical Trials (ISN-ACT) - International Society of Nephrology

The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology community’s participation in clinical trial research.

lite.spr.ly

1 2 1

Reposted by Mo. Elrggal

American Journal of Kidney Diseases @ajkd.bsky.social · Jul 3

On the #AJKDBlog, catch up on these interviews with:

- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia

bit.ly/3ztk4VV (FREE)

3 7

Reposted by Mo. Elrggal

UW Nephrology @uwnephrology.bsky.social · May 9

Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky
@uwmedicine.bsky.social

youtu.be/TeWkmCopuzk

Kathy Tuttle, MD - New Approaches to Blocking Aldosterone & Angiotensinogen for Hypertension or CKD

YouTube video by University of Washington Division of Nephrology

youtu.be

3 8

Reposted by Mo. Elrggal

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · May 9

When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM

We get to see a CJASN abstract! From Divya Bajpai

1 12

Reposted by Mo. Elrggal

American Society of Diagnostic and Interventional Nephrology @asdinnews.bsky.social · May 9

📣 Reminder!
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.

Click here to learn more: www.asdin.org/news/699844/...

#vascularaccess #ASDIN #researchgrant #nephrology

1 1

Reposted by Mo. Elrggal

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · May 9

Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org)
#Nephpearls #NephSky

👉 kdigo.org/guidelines/a...

2 5

Reposted by Mo. Elrggal

Podocyte Talk - Dr. Anass Qasem @podocytetalk.bsky.social · May 10

Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.

#podocytetalk #Nephpearls #Nephrology #CKD

journals.lww.com/cjasn/abstra...

1 2

Reposted by Mo. Elrggal

Nephrology Times @nephtimes.bsky.social · May 8

Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...

EU Approves Sparsentan for Treatment of IgAN | Docwire News

The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).

www.docwirenews.com

3 9

Reposted by Mo. Elrggal

International Society of Renal Nutrition and Metabolism @isrnm-social.bsky.social · May 9

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors

jamanetwork.com/journals/jam...

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors

This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...

jamanetwork.com

1 4

Reposted by Mo. Elrggal

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · May 9

Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD?
#Nephpearls #AskRenal #NephSky

❤️ LIKE for YES (and why?)
❌ X for NO (and why?)

👉 pubmed.ncbi.nlm.nih.gov/39099568/

4 3 8

Mo. Elrggal @kidneyman.bsky.social · May 7

Do you allow hemodialysis patients with permanent HD catheters to shower?
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social

Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study

Patients on hemodialysis using a central venous catheter (CVC) are often advised not to shower due to infection risk. This study assessed practices and attitudes of patients and health care providers ...

www.ajkd.org

1

Reposted by Mo. Elrggal

Kidney International @kidneyint.bsky.social · May 7

Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD

doi.org/10.1016/j.kint.2025.02.018

Original article: doi.org/10.1016/j.kint.2025.01.023

#KICommentary #MedSky #NephSky #polycystickidneydisease

3 3

Reposted by Mo. Elrggal

Maddalena Marasà @madmarasa.bsky.social · May 6

Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases?

www.jci.org/articles/vie...

#NephSky #MedSky

Journal of Clinical Investigation @jci.org · May 6

Aberrant activation of complement's alternative pathway may be the missing link in understanding how vascular and systemic inflammation accelerates chronic kidney disease progression.

Read more in the review by Jalal, Thurman & Smith: buff.ly/DwHd0ut

1 3

Reposted by Mo. Elrggal

American Journal of Kidney Diseases @ajkd.bsky.social · May 7

Editorial by Harshil A. Fichadiya and John C. Lieske:

Do Topiramate and Zonisamide Cause Kidney Stones?

bit.ly/FichadiyaED25 (FREE)

1 2

Reposted by Mo. Elrggal

Kidney International @kidneyint.bsky.social · May 7

#KIControversies in Nephrology
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039

#MedSky #NephSky #kidneytransplant

5 10

Mo. Elrggal @kidneyman.bsky.social · May 3

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases

ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical

academic.oup.com

2

Reposted by Mo. Elrggal

American Journal of Kidney Diseases @ajkd.bsky.social · Apr 19

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

bit.ly/3ZdrYxb #OpenAccess

#VisualAbstract #CKD

2 7

Mo. Elrggal @kidneyman.bsky.social · Apr 7

#nephsky

Mo. Elrggal @kidneyman.bsky.social · Apr 7

Despite my ranking, I am still getting both winners at the finals.. @nephmadness.bsky.social

Mo. Elrggal @kidneyman.bsky.social · Apr 7

Despite my ranking, I am still getting both winners at the finals.. @nephmadness.bsky.social

Mo. Elrggal @kidneyman.bsky.social · Apr 3

Yes!
Didn't think my post will generate such #trashtalks

1 2